Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQ101 in moderate to severe alopecia areata
NCT05589610Phase 2Completed
- Sponsor
- Equillium, Inc.
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules, PEGylated Peptides
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of BNZ-1 in alopecia areata, sponsored by Equillium, Inc. Primary endpoint: Treatment Emergent Adverse Events at Week 28. Started Dec 2022; status: completed.
02
Drugs
BNZ-1
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05589610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05589610.